Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Econazole** is a topical antifungal medication primarily used to treat various fungal and yeast infections of the skin, including athlete's foot (tinea pedis), jock itch (tinea cruris), ringworm (tinea corporis), tinea versicolor, and cutaneous candidiasis[2][3][4][5][7]. It is available as a cream or foam for topical application. Econazole acts by inhibiting lanosterol 14-α demethylase, a cytochrome P-450 enzyme essential for converting lanosterol to ergosterol—a critical component of fungal cell membranes. This inhibition disrupts membrane integrity, leading to increased permeability and leakage of cellular contents, ultimately killing the fungus[4][8]. Additional mechanisms may include interference with membrane phospholipids and impairment of other cellular processes in fungi[4]. Econazole has some activity against Gram-positive bacteria but is mainly used as an antifungal agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on econazole.